Expertise in
2
conditions

Craig A. Gedye

New Lambton Heights, 
Newcastle, NSW, AU 
Expertise in
2
conditions
New Lambton Heights, 
Newcastle, NSW, AU 
OverviewLocationsClinical Research

Overview

Craig Gedye practices in Newcastle, Australia. Mr. Gedye is highly rated in 2 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Melanoma, and Glioblastoma.

His clinical research consists of co-authoring 77 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

New Lambton Heights, Newcastle, NSW, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
TheraP: A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (ANZUP Protocol 1603)
TheraP: A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (ANZUP Protocol 1603)
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Other, Drug
Study Drug: Cabazitaxel
Study Phase: Phase 2
A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602).
A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602).
Enrollment Status: Unknown
Publish Date: February 16, 2022
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
View 2 Less Clinical Trials

77 Total Publications

In vitro and in vivo derived macrophages occupy distinct phenotypic states.
In vitro and in vivo derived macrophages occupy distinct phenotypic states.
Journal: bioRxiv : the preprint server for biology
Published: September 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Gedye's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile